SMITHFIELD – New Haven, Conn.-based Alexion Pharmaceuticals Inc. reported a 17 percent year-over-year decline in net income for the 2017 third quarter to $78 million, or 35 cents per diluted share, which fell 7 cents over the year. The biopharmaceutical company that focuses on drugs for rare diseases increased third-quarter revenue by 7.5 percent year…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.